BTBenjamin Taylor

Benjamin Taylor

*This is an algorithmically generated author record based on publicly available information.

Benjamin Taylor has a total of 134 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Enhancement of a nuclear factor of activated T cells (NFAT) reporter for the study of G protein-coupled receptors

    by Edward Wills, Anjana Saji, Jonathan Sumner, Aman Khan, Claudia M. Sisk, Mona Shehata, Benjamin Taylor, Graham Ladds

    Cell-based assays are fundamental to G protein-coupled receptor (GPCRs) drug discovery. As the field strives to increase the use of physiological cell types with endogenous receptor expression, enhancing the sensitivity of simple-to-use assays unlocks new screening modalities. Here, we enhanced the responsivity of a Nuclear Factor of Activated T cells response element (NFAT-RE) reporter, by concatenating the IL-2 promoter-derived triplicate-binding sites, to produce three nano-luciferase reporter constructs termed NFAT 2X, NFAT 3X and NFAT 4X. Our enhanced reporters demonstrate larger maximal Fold Induction (FI) when co-expressed with both primarily and secondarily Gα q/11 -coupled GPCRs. This pattern was maintained when stimulating endogenous GPCRs in a panel of immortalised cell lines (HEK293, HeLa, A549, and HEK293T) and allowed us to observe Sphingosine-1-Phosphate (S1P)-mediated signalling in primary human CD8 + T cells via CRISPR/Cas9 knock-in. Our NFAT-reporter T cells demonstrate the reporters potential for use in bi-allelic expression systems and primary cell types.

  • Open Access

    Large-scale visualisation of α-synuclein oligomers in Parkinson's disease brain tissue

    by Rebecca Andrews, Bin Fu, Christina E. Toomey, Jonathan C. Breiter, Joanne Lachica, Ru Tian, Joseph S. Beckwith, Lisa-Maria Needham, Gregory J. Chant, Camille Loiseau, et al.

    Parkinson's disease (PD) is a common neurodegenerative condition characterised by the presence in the brain of large intraneuronal aggregates, known as Lewy bodies and Lewy neurites, containing fibrillar α-synuclein. According to the amyloid hypothesis, these large end-stage species form from smaller soluble protein assemblies, often termed oligomers, which are proposed as early drivers of pathogenesis. To date, however, this hypothesis has remained controversial, at least in part because it has not been possible to directly visualise oligomeric aggregates in human brain tissue. Therefore, their presence, abundance and distributions have remained elusive. Here, we present ASA-PD (Advanced Sensing of Aggregates - Parkinson's Disease), an imaging method to generate large-scale α-synuclein oligomer maps in post-mortem human brain tissue. We combined autofluorescence suppression with single-molecule fluorescence methods, which together, enable the detection of nanoscale α-synuclein aggregates. To demonstrate the utility of this platform, we captured ~1.2 million oligomers from the anterior cingulate cortex in human post-mortem brain samples from PD and healthy control patients. Our data revealed a specific subpopulation of nanoscale oligomers that represent an early hallmark of the proteinopathy that underlies PD. We anticipate that quantitative information about oligomer distributions provided by ASA-PD will enable mechanistic studies to reveal the pathological processes caused by α-synuclein aggregation.


  • Open Access

    CardioVascular Burden Of Narcolepsy Disease (CV-BOND): A Real-World Evidence Study

    by R.H. Ben-Joseph, R. Saad, J. Black, E.C. Dabrowski, B. Taylor, S. Gallucci, V.K. Somers

  • Open Access

    Author Correction: Universal toxin-based selection for precise genome engineering in human cells

    by Songyuan Li, Nina Akrap, Silvia Cerboni, Michelle J. Porritt, Sandra Wimberger, Anders Lundin, Carl Möller, Mike Firth, Euan Gordon, Bojana Lazovic, et al.


  • Open Access

    Universal toxin-based selection for precise genome engineering in human cells

    by Songyuan Li, Nina Akrap, Silvia Cerboni, Michelle J. Porritt, Sandra Wimberger, Anders Lundin, Carl Möller, Mike Firth, Euan Gordon, Bojana Lazovic, et al.

    Prokaryotic restriction enzymes, recombinases and Cas proteins are powerful DNA engineering and genome editing tools. However, in many primary cell types, the efficiency of genome editing remains low, impeding the development of gene- and cell-based therapeutic applications. A safe strategy for robust and efficient enrichment of precisely genetically engineered cells is urgently required. Here, we screen for mutations in the receptor for Diphtheria Toxin (DT) which protect human cells from DT. Selection for cells with an edited DT receptor variant enriches for simultaneously introduced, precisely targeted gene modifications at a second independent locus, such as nucleotide substitutions and DNA insertions. Our method enables the rapid generation of a homogenous cell population with bi-allelic integration of a DNA cassette at the selection locus, without clonal isolation. Toxin-based selection works in both cancer-transformed and non-transformed cells, including human induced pluripotent stem cells and human primary T-lymphocytes, as well as it is applicable also in vivo, in mice with humanized liver. This work represents a flexible, precise, and efficient selection strategy to engineer cells using CRISPR-Cas and base editing systems.


  • Open Access

    CRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs

    by Matthew A. Coelho, Etienne De Braekeleer, Mike Firth, Michal Bista, Sebastian Lukasiak, Maria Emanuela Cuomo, Benjamin J. M. Taylor

    Precise genome editing using CRISPR-Cas9 is a promising therapeutic avenue for genetic diseases, although off-target editing remains a significant safety concern. Guide RNAs shorter than 16 nucleotides in length effectively recruit Cas9 to complementary sites in the genome but do not permit Cas9 nuclease activity. Here we describe CRISPR Guide RNA Assisted Reduction of Damage (CRISPR GUARD) as a method for protecting off-targets sites by co-delivery of short guide RNAs directed against off-target loci by competition with the on-target guide RNA. CRISPR GUARD reduces off-target mutagenesis while retaining on-target editing efficiencies with Cas9 and base editor. However, we discover that short guide RNAs can also support base editing if they contain cytosines within the deaminase activity window. We explore design rules and the universality of this method through in vitro studies and high-throughput screening, revealing CRISPR GUARD as a rapidly implementable strategy to improve the specificity of genome editing for most genomic loci. Finally, we create an online tool for CRISPR GUARD design.


  • Open Access

    DNA stretching induces Cas9 off-target activity

    by Matthew D. Newton, Benjamin J. Taylor, Rosalie P. C. Driessen, Leonie Roos, Nevena Cvetesic, Shenaz Allyjaun, Boris Lenhard, Maria Emanuela Cuomo, David S. Rueda

    CRISPR/Cas9 is a powerful genome-editing tool, but spurious off-target edits present a barrier to therapeutic applications. To understand how CRISPR/Cas9 discriminates between on-targets and off-targets, we have developed a single-molecule assay combining optical tweezers with fluorescence to monitor binding to λ-DNA. At low forces, the Streptococcus pyogenes Cas9 complex binds and cleaves DNA specifically. At higher forces, numerous off-target binding events appear repeatedly at the same off-target sites in a guide-RNA-sequence-dependent manner, driven by the mechanical distortion of the DNA. Using single-molecule Förster resonance energy transfer (smFRET) and cleavage assays, we show that DNA bubbles induce off-target binding and cleavage at these sites, even with ten mismatches, as well as at previously identified in vivo off-targets. We propose that duplex DNA destabilization during cellular processes (for example, transcription, replication, etc.) can expose these cryptic off-target sites to Cas9 activity, highlighting the need for improved off-target prediction algorithms.


  • Open Access

    BE-FLARE: a fluorescent reporter of base editing activity reveals editing characteristics of APOBEC3A and APOBEC3B

    by Matthew A. Coelho, Songyuan Li, Luna Simona Pane, Mike Firth, Giovanni Ciotta, Jonathan D. Wrigley, Maria Emanuela Cuomo, Marcello Maresca, Benjamin J. M. Taylor

    Base Editing is a precise genome editing method that uses a deaminase-Cas9 fusion protein to mutate cytidine to thymidine in target DNA in situ without the generation of a double-strand break. However, the efficient enrichment of genetically modified cells using this technique is limited by the ability to detect such events. We have developed a Base Editing FLuorescent Activity REporter (BE-FLARE), which allows for the enrichment of cells that have undergone editing of target loci based on a fluorescence shift from BFP to GFP. We used BE-FLARE to evaluate the editing efficiency of APOBEC3A and APOBEC3B family members as alternatives deaminase domains to the rat APOBEC1 domain used in base editor 3 (BE3). We identified human APOBEC3A and APOBEC3B as highly efficient cytidine deaminases for base editing applications with unique properties. Using BE-FLARE to report on the efficiency and precision of editing events, we outline workflows for the accelerated generation of genetically engineered cell models and the discovery of alternative base editors.


  • Open Access

    Decoding non-random mutational signatures at Cas9 targeted sites

    by Amir Taheri-Ghahfarokhi, Benjamin J M Taylor, Roberto Nitsch, Anders Lundin, Anna-Lina Cavallo, Katja Madeyski-Bengtson, Fredrik Karlsson, Maryam Clausen, Ryan Hicks, Lorenz M Mayr, et al.

    The mutation patterns at Cas9 targeted sites contain unique information regarding the nuclease activity and repair mechanisms in mammalian cells. However, analytical framework for extracting such information are lacking. Here, we present a novel computational platform called Rational InDel Meta-Analysis (RIMA) that enables an in-depth comprehensive analysis of Cas9-induced genetic alterations, especially InDels mutations. RIMA can be used to quantitate the contribution of classical microhomology-mediated end joining (c-MMEJ) pathway in the formation of mutations at Cas9 target sites. We used RIMA to compare mutational signatures at 15 independent Cas9 target sites in human A549 wildtype and A549-POLQ knockout cells to elucidate the role of DNA polymerase θ in c-MMEJ. Moreover, the single nucleotide insertions at the Cas9 target sites represent duplications of preceding nucleotides, suggesting that the flexibility of the Cas9 nuclease domains results in both blunt- and staggered-end cuts. Thymine at the fourth nucleotide before protospacer adjacent motif (PAM) results in a two-fold higher occurrence of single nucleotide InDels compared to guanine at the same position. This study provides a novel approach for the characterization of the Cas9 nucleases with improved accuracy in predicting genome editing outcomes and a potential strategy for homology-independent targeted genomic integration.


  • Open Access

    Mapping the sugar dependency for rational generation of a DNA-RNA hybrid-guided Cas9 endonuclease

    by Fernando Orden Rueda, Michal Bista, Matthew D. Newton, Anne U. Goeppert, M. Emanuela Cuomo, Euan Gordon, Felix Kröner, Jon A. Read, Jonathan D. Wrigley, David Rueda, et al.

    The CRISPR–Cas9 RNA-guided endonuclease system allows precise and efficient modification of complex genomes and is continuously developed to enhance specificity, alter targeting and add new functional moieties. However, one area yet to be explored is the base chemistry of the associated RNA molecules. Here we show the design and optimisation of hybrid DNA–RNA CRISPR and tracr molecules based on structure-guided approaches. Through careful mapping of the ribose requirements of Cas9, we develop hybrid versions possessing minimal RNA residues, which are sufficient to direct specific nuclease activity in vitro and in vivo with reduced off-target activity. We identify critical regions within these molecules that require ribose nucleotides and show a direct correlation between binding affinity/stability and cellular activity. This is the first demonstration of a non-RNA-guided Cas9 endonuclease and first step towards eliminating the ribose dependency of Cas9 to develop a XNA-programmable endonuclease.